Soligenix Inc SNGX

US Biotechnology
$0.37 β–Ό -0.29% ($0.00)
🗓️ Earnings Next Week
Open $0.37
Prev Close $0.38
Day Range $0.36 – $0.40
52W Range $0.28 – $6.23
Market Cap $8.14M
Beta 2.01
EPS (TTM) $-1.97

πŸ“‹ Company Profile

IndustryBiotechnology
CountryUS
ExchangeNASDAQ NMS - GLOBAL MARKET
CurrencyUSD
IPO Date1994-04-04
Shares Out.14,820,000
Websitesoligenix.com/ β†—
Phone13023513367
Employees14
Net Income-$2.8M
Free Cash Flow-$10.8M
Total Assets$6.9M
Total Liabilities$3.8M
Equity$3.1M
About Soligenix Inc

Soligenix Inc is a late-stage biopharmaceutical company based in the United States. It focuses on developing and commercializing products to treat rare diseases where there is an unmet medical need. The company operates through two business segments namely: The Public Health Solutions business segment includes development programs for RiVax, a ricin toxin vaccine candidate, GX943, a therapeutic candidate for antibiotic resistant and emerging infectious disease and various vaccine programs, including a program targeting filoviruses and CiVax; and The Specialized BioTherapeutics business segment is developing and moving toward potential commercialization of HyBryte, utilizing topical synthetic hypericin activated with safe visible light for the treatment of cutaneous T-cell lymphoma (CTCL).

Soligenix Inc is a publicly traded company under the ticker symbol SNGX on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.

πŸ“Š Analyst Ratings

7 analysts (2026-07-01)

Strong Buy 2
Buy 4
Hold 1

πŸ“° Latest News for SNGX

πŸ‘₯ Related Stocks